Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Brooks Lab.
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 15.30 | 12.61 | 15.70 | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 20.52 | 23.32 | 25.51 | 23.45 | 16.57 |
| Expenses + | 23.85 | 16.31 | 19.61 | 25.42 | 25.12 | 27.25 | 19.85 | 24.20 | 22.02 | 24.58 | 22.38 | 20.93 | 15.84 |
| Operating Profit | -8.55 | -3.70 | -3.91 | -1.10 | -3.37 | -9.53 | -1.92 | -3.41 | -1.50 | -1.26 | 3.13 | 2.52 | 0.73 |
| OPM % | -55.88% | -29.34% | -24.90% | -4.52% | -15.49% | -53.78% | -10.71% | -16.40% | -7.31% | -5.40% | 12.27% | 10.75% | 4.41% |
| Other Income + | 0.45 | 0.03 | 0.05 | 0.09 | 0.16 | 0.65 | 0.07 | 0.20 | 0.03 | 0.62 | 7.15 | 6.13 | 5.32 |
| Interest | 0.75 | 0.18 | 0.17 | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.28 | 0.26 | 0.30 | 0.28 | 0.16 |
| Depreciation | 2.33 | 0.44 | 0.44 | 0.44 | 0.43 | 0.46 | 0.40 | 0.43 | 0.38 | 0.39 | 0.39 | 0.39 | 0.39 |
| Profit before tax | -11.18 | -4.29 | -4.47 | -1.64 | -3.85 | -9.61 | -2.41 | -3.96 | -2.13 | -1.29 | 9.59 | 7.98 | 5.50 |
| Tax % | -15.21% | 0.00% | 0.00% | 0.00% | 0.78% | 0.00% | 0.00% | 0.00% | 0.00% | 13.95% | 0.00% | 0.00% | 0.00% |
| Net Profit + | -9.48 | -4.29 | -4.47 | -1.64 | -3.88 | -9.61 | -2.41 | -3.96 | -2.13 | -1.46 | 9.58 | 7.98 | 5.50 |
| EPS in Rs | -1.92 | -1.64 | -1.71 | -0.62 | -1.48 | -3.66 | -0.92 | -1.51 | -0.81 | -0.50 | 3.25 | 2.71 | 1.87 |
Financials of Brooks Lab.
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| Sales + | 77 | 91 | 63 | 79 | 83 | 89 |
| Expenses + | 77 | 105 | 93 | 97 | 91 | 84 |
| Operating Profit | 1 | -14 | -30 | -18 | -8 | 5 |
| OPM % | 1% | -16% | -47% | -22% | -10% | 6% |
| Other Income + | 1 | 1 | 1 | 1 | 1 | 19 |
| Interest | 3 | 3 | 2 | 1 | 1 | 1 |
| Depreciation | 7 | 7 | 7 | 2 | 2 | 2 |
| Profit before tax | -9 | -24 | -38 | -20 | -10 | 22 |
| Tax % | 115% | -19% | -19% | 0% | 2% | |
| Net Profit + | -19 | -19 | -31 | -20 | -10 | 22 |
| EPS in Rs | -7.40 | -4.31 | -7.97 | -7.46 | -3.38 | 7.33 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Brooks Lab.
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 26 | 29 | 29 |
| Reserves | 54 | 63 | 49 | 39 | 69 | 86 |
| Borrowings + | 31 | 25 | 7 | 6 | 8 | 8 |
| Other Liabilities + | 52 | 83 | 29 | 19 | 18 | 16 |
| Total Liabilities | 162 | 196 | 110 | 90 | 124 | 140 |
| Fixed Assets + | 108 | 110 | 15 | 14 | 14 | 13 |
| CWIP | 1 | 15 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 64 | 43 | 74 | 86 |
| Other Assets + | 54 | 71 | 31 | 34 | 36 | 40 |
| Total Assets | 162 | 196 | 110 | 90 | 124 | 140 |
Financials of Brooks Lab.
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 4 | -37 | -14 | -10 | 3 |
| Cash from Investing Activity + | -5 | -25 | 0 | 0 | -45 |
| Cash from Financing Activity + | 1 | 64 | 11 | 10 | 42 |
| Net Cash Flow | 0 | 2 | -3 | 0 | -0 |
| Free Cash Flow | -1 | -62 | -15 | -10 | 2 |
| CFO/OP | 1,519% | 261% | 48% | 56% | -26% |
Financials of Brooks Lab.
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 65 | 71 | 74 | 75 | 88 |
| Inventory Days | 178 | 157 | 80 | 60 | 61 |
| Days Payable | 233 | 159 | 165 | 97 | 90 |
| Cash Conversion Cycle | 9 | 68 | -12 | 38 | 59 |
| Working Capital Days | -85 | 34 | -37 | 34 | 43 |
| ROCE % | -16% | -30% | -25% | -10% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…